Taylor R Brooks

8PUBLICATIONS
106CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Oct 29, 2025
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy.

Miriam M Fonseca, Oriana Gelblung, Sarah D Pennypacker

|Aug 05, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Zachary D Epstein-Peterson, Anath C Lionel, Ashlee Joseph

|Jul 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Taylor R Brooks, Emily C Zabor, Yohanna B Bedelu

|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.

Rahul S Bhansali, Fredrik Ellin, Thomas Relander

Pageof 2